Q2 Earnings Forecast for BNTC Issued By HC Wainwright

Benitec Biopharma Inc. (NASDAQ:BNTC) – Analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Benitec Biopharma in a research note issued to investors on Monday, December 16th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will earn ($0.27) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($4.33) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

A number of other brokerages have also weighed in on BNTC. Robert W. Baird initiated coverage on shares of Benitec Biopharma in a report on Friday, December 13th. They issued an “outperform” rating and a $30.00 price objective for the company. Oppenheimer began coverage on shares of Benitec Biopharma in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 price target for the company. Guggenheim reaffirmed a “buy” rating and set a $17.00 price objective on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. JMP Securities lifted their price objective on Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a report on Monday, October 14th. Finally, Baird R W upgraded Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $24.43.

Benitec Biopharma Stock Performance

NASDAQ:BNTC traded down $0.03 during mid-day trading on Thursday, reaching $11.81. The stock had a trading volume of 2,351 shares, compared to its average volume of 46,136. The stock has a market capitalization of $274.18 million, a P/E ratio of -4.16 and a beta of 0.88. The firm has a 50 day moving average price of $10.73 and a two-hundred day moving average price of $9.38. Benitec Biopharma has a one year low of $2.69 and a one year high of $13.29.

Institutional Investors Weigh In On Benitec Biopharma

Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in Benitec Biopharma by 20.3% during the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 1,102 shares during the period. Acuta Capital Partners LLC bought a new stake in Benitec Biopharma in the 3rd quarter worth about $274,000. Simplify Asset Management Inc. bought a new stake in Benitec Biopharma in the 2nd quarter worth approximately $358,000. Geode Capital Management LLC increased its position in shares of Benitec Biopharma by 31.3% during the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock valued at $772,000 after purchasing an additional 20,012 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in Benitec Biopharma in the second quarter worth approximately $5,881,000. 52.19% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Suvretta Capital Management, L purchased 42,000 shares of Benitec Biopharma stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $9.60 per share, for a total transaction of $403,200.00. Following the completion of the transaction, the director now directly owns 7,957,365 shares of the company’s stock, valued at $76,390,704. This represents a 0.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.30% of the stock is owned by insiders.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.